Author:
Zheng Canbin,Zheng Yongping,Chen Xi,Zhong Xianyang,Zheng Xiaobin,Yang Shuhui,Zheng Zihui
Abstract
Abstract
Background
Studies on chemerin/chemokine-like receptor-1 have mainly focused on adipose and liver with the intestinal tissues largely overlooked. In this study conducted on obese mice, we have explored: 1) CMKLR1 expression in the ileums; 2) CMKLR1 inhibitor α-NETA on body weight and intestinal mucosa integrity hence the impact on hepatic steatosis and pathway involved.
Methods
Nineteen male C57BL/6 mice were randomly divided into five groups: normal diet group (ND), high-fat diet group (HFD), HFD + α-NETA group (NETA), HFD + PD98059 group (PD) and HFD + α-NETA + PD98059 group (NETA + PD). Mice were fed either with a chow diet or HFD for 12 weeks. At 12th week, mice of ND were put on the diet as before; mice of NETA received daily treatments of α-NETA (30 mg/kg) via gavage; mice of PD received daily treatment of PD98059 via tail vein injection; mice of NETA + PD received daily treatment of α-NETA + PD98059, all for another 4 weeks. At the time intervention ended, mice were sacrificed. The body weight, the liver pathologies were assessed. Ileal CMKLR1 mRNA was evaluated by rtPCR; ZO-1, ERK1/2 protein expression of ileal tissues by western blotting; liver TNF-α and serum endotoxin by Elisa.
Results
More weight gains in mice of HFD than ND (37.90 ± 3.00 g) vs (24.47 ± 0.50 g), P = 0.002; α-NETA reduced the body weight (33.22 ± 1.90 g) vs (37.90 ± 3.00 g), P = 0.033; and further reduced by NETA + PD98059: (31.20 ± 1.74 g) vs (37.30 ± 4.05 g), P = 0.032. CMKLR1 mRNA expression was up-regulated in ileum in group HFD compared with ND and down-regulated by α-NETA. Steatosis was only alleviated in group PD + NETA with less weight gain. No impact of α-NETA on ileal ZO-1 or pERK with western blotting, and no endotoxin level changes were detected. TNF-α was higher in group HFD than in group ND, while no significant difference between other groups.
Conclusions
CMKLR1 mRNA was up-regulated in the ileum of obese mice and down-regulated by α-NETA along with a body weight control collaborating with ERK inhibitor PD98059. Steatosis was alleviated in a weight dependent way. α-NETA has no influence on intestinal mucosal integrity and no impact on steatohepatitis progression.
Funder
Guangdong medical research foundation
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Endocrinology, Diabetes and Metabolism
Reference38 articles.
1. Türker F, Oral A, Şahin T, et al. Does the FT3-to-FT4 ratio easily predict the progression of NAFLD and NASH cirrhosis? J Int Med Res. 2021;49(11):3000605211056841. https://doi.org/10.1177/03000605211056841.PMCID:PMC8593317.
2. Chao S, Jian-Gao F, Liang Q. Potential epigenetic mechanism in non-alcoholic Fatty liver disease. Int J Mol Sci. 2015;16(3):5161–79. https://doi.org/10.3390/ijms16035161.
3. Han R, Ma J, Li H. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota. Front Med. 2018;12(6):645–57. https://doi.org/10.1007/s11684-018-0645-9. PMID: 30178233.
4. Zhu JZ, Yi HW, Huang W, Pang T, Zhou HP, Wu XD. Fatty liver diseases, mechanisms, and potential therapeutic plant medicines. Chin J Nat Med. 2020;18(3):161–8 (PMID: 32245585).
5. Etienne-Mesmin L, Gewirtz AT, et al. Microbiota-liver axis in hepatic disease. Hepatology. 2014;59:328–39. https://doi.org/10.1002/hep.26494.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献